Association of follicular lymphoma risk with BRCA2 N372H Polymorphism in Slovak population

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1173-1178

  Šalagovič, Ján ^a   Klimčáková, Lucia ^a   Ilenčíková, Denisa ^b   Kafková, Adriana ^c  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

Author keywords

DNA repair genes; Follicular lymphoma; Single nucleotide polymorphisms

Indexed keywords

ARGININE; ASPARAGINE; BRCA2 PROTEIN; HISTIDINE; ISOLEUCINE; LIGASE; LIGASE 4; LYSINE; RAG1 PROTEIN; THREONINE; UNCLASSIFIED DRUG; VALINE; WERNER SYNDROME PROTEIN; BRCA2 PROTEIN, HUMAN; DNA; EXODEOXYRIBONUCLEASE; HOMEODOMAIN PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE (ATP); RAG 1 PROTEIN; RAG-1 PROTEIN; RECQ HELICASE; WRN PROTEIN, HUMAN;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELTING POINT; MOLECULAR PROBE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SLOVAKIA; WILD TYPE; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BRCA2 PROTEIN; CASE-CONTROL STUDIES; DNA; DNA LIGASES; EXODEOXYRIBONUCLEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMEODOMAIN PROTEINS; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECQ HELICASES; RISK FACTORS; SLOVAKIA; YOUNG ADULT;

EID: 84866272444     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9925-9     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCANN Int J Cancer. 2010;127(12):2893- 917.
2. Hartge P. Estimating the burden of disease and the benefits of prevention. Epidemiology. 2006;17(5):498-9.
3. Hartge P, Wang SS. Overview of the etiology and epidemiology of lymphoma. In: Mauch PM, Armitage JO, Coiffier B, Dalla- Favera R, Harris NL, editors. Non-Hodgkin's Lymphomas. Philadelphia: Lippincott Williams& Wilkins; 2004. p. 711-27.
4. Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol. 2005;128:792-6.
5. Iscovich J, Parkin DM. Risk of cancer in migrants and their descendants in Israel: I. Leukaemias and lymphomas. Int J Cancer. 1997;70:649-53.
6. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27-38.
7. Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109:3479-88.
8. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20:5580-94.
9. Dyer MJS. The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies. Int J Hematol. 2003;77:315-20.
10. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-62.
11. Bende RJ, Smit LA, van Noesel CJM. Molecular pathways in follicular lymphoma. Leukemia. 2006;21:18-29.
12. Hill DA, Wang SS, Cerhan JR, et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood. 2006;108:3161-7.
13. Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA doublestranded breaks in somatic hypermutation of immunoglobulin genes. Nature. 2000;408:216-21.
14. Shen M, Zheng T, Lan Q, Zhang Y, Zahm SH, Wang SS, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet. 2006;119: 659-68.
15. Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15:258-65.
16. Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cellcycle-control genes. Am J Hum Genet. 2006;78(3):464-79.
17. Roddam PL, Rollinson S, O'Driscoll M, et al. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet. 2002;39(12):900-5.
18. Kuschel B, Auranen A, McBride S, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002;11(12):1399-407.
19. Figueroa JD, Malats N, Rothman N, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis. 2007;28(8):1788-93.
20. Palli D, Falchetti M, Masala G, et al. Association between the BRCA2 N372H variant and male breast cancer risk: a populationbased case-control study in Tuscany, Central Italy. BMC Cancer. 2007;7:170.
21. Hiom K, Melek M, Gellert M. DNAtransposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell. 1998;94:463-70.
22. Corneo B, Moshous D, Gungor T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001;97:2772-6.
23. Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 2001; 97:81-8.
24. Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNArepair protein XRCC4 in tumorigenesis, genomic stability and development. Nature. 2000;404:897-900.
25. Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000;26:362-4.
26. Spurdle AB, Hopper JL, Chen X, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev. 2002;11:413-6.
27. Auranen A, Spurdle AB, Chen X, et al. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int J Cancer. 2003;103:427-30.
28. Wenham RM, Schildkraut JM, McLean K, et al. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003;9:4396-403.
29. Cox DG, Hankinson SE, Hunter DJ. No association between BRCA2 N372H and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:1353-4.
30. The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310-6.
31. Scott K, Adamson PJ, Barrans SL, Worrillow LJ, et al. RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma. Blood. 2007;109(12):552-3.
32. Fuks F, Milner J, Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene. 1998;17: 2531-4.
33. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91: 1336-44.
34. Zhoucun A, Zhang S, Yang Y, et al. The common variant N372H in BRCA2 gene may be associated with idiopathic male infertility with azoospermia or severe oligozoospermia. Eur J Obstet Gynecol Reprod Biol. 2006;124:61-4.
35. Ozgenc A, Loeb LA. Current advances in unraveling the function of the Werner syndrome protein. Mutat Res. 2005;577(1-2): 237-51.
36. Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome. Cancer Epidemiol Biomarkers Prev. 1996;5:239-46.